AGIO Agios Pharmaceuticals, Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
AGIO Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$29.25
Analyst Target
$38.88
+32.9%
Upside
52W High
$46.0
52W Low
$22.24
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
AGIO's Advanced Deterministic Scorecard reveals severe financial distress, with a Piotroski F-Score of 1/9 indicating extreme weakness in operational and financial health. The absence of an Altman Z-Score and the company's negative profitability metrics—such as a -608.89% operating margin and -30.20% ROE—highlight deep operational inefficiencies. Despite strong revenue growth (86.1% YoY), the company remains unprofitable and generates no earnings, undermining long-term sustainability. Insider selling activity totaling $1.17M over six months further signals lack of confidence among leadership. The stock trades at a premium valuation (Price/Sales of 31.72) with no intrinsic value support, making it vulnerable to downside pressure.
Key Strengths
Strong revenue growth of 86.1% YoY indicates market traction and product demand
High current and quick ratios (11.46 and 10.53) suggest exceptional short-term liquidity
Low debt-to-equity ratio (0.03) reflects minimal financial leverage and low solvency risk
Analyst consensus recommends 'buy' with a target price of $38.88, implying upside potential
Recent quarter beat rate of 50% (2/4) shows some earnings consistency despite losses
Key Risks
Piotroski F-Score of 1/9 signals severe financial deterioration and operational failure
Negative operating margin (-608.89%) and zero profit margin indicate unsustainable business model
Insider selling by key executives (CEO, CFO, officers) reflects bearish sentiment
No dividend, no free cash flow, and no earnings growth undermine investor confidence
Stock trades at a high Price/Sales of 31.72, far above industry average, suggesting overvaluation
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare AGIO against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning AGIO from our newsroom.
Newest → oldest
No matching news yet.